Advertisement
Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow My Folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, W.
Right arrow Articles by Horowitz, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, W.
Right arrow Articles by Horowitz, S. H.
Related Collections
Right arrow All Headache
Right arrow Migraine
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)

Neurology 2003;60:120-121
© 2003 American Academy of Neurology
Brief Communications

Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil

Wengui Yu, MD PhD and Steven H. Horowitz, MD

From the Division of Neurology, University of Missouri–Columbia.

Address correspondence and reprint requests to Dr. Wengui Yu, Neurovascular Service, Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, Box 0114, San Francisco, CA 94143; e-mail: wyu_1998{at}yahoo.com

Gene mutations within the P/Q type neuronal calcium channel in familial hemiplegic migraine (FHM) suggest a therapeutic role for calcium-channel blockade. The authors have previously reported abortive therapy of FHM with IV verapamil. Here the authors describe four cases of sporadic hemiplegic migraine (SHM) responsive to verapamil, administered either orally or IV. The findings indicate that verapamil is effective therapy for both SHM and FHM.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. A. Gelfand, H. J. Fullerton, and P. J. Goadsby
Child Neurology: Migraine with aura in children
Neurology, August 3, 2010; 75(5): e16 - e19.
[Abstract] [Full Text] [PDF]

Home page
 CephalalgiaHome page
A Jacob, K Mahavish, A Bowden, E. Smith, P Enevoldson, and R. White
Imaging Abnormalities in Sporadic Hemiplegic Migraine on Conventional MRI, Diffusion and Perfusion MRI and MRS
Cephalalgia, August 1, 2006; 26(8): 1004 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 CephalalgiaHome page
I Domitrz, A Kostera-Pruszczyk, and H Kwiecinski
A single-fibre EMG Study of Neuromuscular Transmission in Migraine Patients
Cephalalgia, October 1, 2005; 25(10): 817 - 821.
[Abstract] [Full Text] [PDF]

Home page
 CephalalgiaHome page
L. Thomsen and J Olesen
Sporadic Hemiplegic Migraine
Cephalalgia, December 1, 2004; 24(12): 1016 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. C. Lastimosa, W. Yu, and S. H. Horowitz
Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil
Neurology, September 9, 2003; 61(5): 721 - 722.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil
Augusto Cezar Lastimosa
Neurology Online, 5 Mar 2003 [Full text]
Reply to Letter to the Editor
Wengui Yu
Neurology Online, 5 Mar 2003 [Full text]

Advertisement